AKT1 and stroke disorder: Thus, it was found that LM22A-4-SMB-3 improves post-stroke recovery in a mouse model of ischemic stroke, reduces apoptosis and glial activation, increases the phosphorylation of TrkB and Akt, boosts neurogenesis, and diminishes brain atrophy after the stroke [68].